BIO to Transition Agricultural and Environmental Biotech Workstreams  Key Senior Hires Bolster Focus on Regulatory Affairs, Emerging Companies   and Economic Growth   Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work of its Agriculture and Environment (A&E) section to other organizations.  This change is intended to enable an enhanced strategic focus on each of these respective areas of biotechnology and will be effective July 1, 2025. In support of this transition, BIO announced the hiring of two new senior executives to lead Regulatory Affairs and a new “Center of Excellence” focused on Emerging Companies & Economic Growth.   “The field of biotechnology is increasingly diverse, with great threats and significant opportunities,” said John F. Crowley, President and CEO, BIO. “In consultation with the BIO Executive Committee and the Agriculture and Environment Governing Board, BIO has determined that these organizational changes will enable greater focus and impact on behalf of our healthcare members, and will sharpen our advocacy work on critical policy priorities for the improvement of human health – modernizing the FDA’s regulatory processes; building back a robust biopharmaceutical manufacturing base across the US and our allies; preserving strong IP protections; fostering capital formation; protecting our national security; and enabling 21st Century access to medicines. At the same time, this change will enable A&E member companies to enhance their focus on agricultural and environmental biotech at expert third-party organizations.”   BIO also announced the addition of two new senior leaders to its healthcare team.   Annetta Beauregard will join BIO effective June 9, 2025 as SVP, Science & Regulatory Affairs, where she will spearhead BIO’s regulatory policy strategy and…

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the United States and the cornerstone of America’s biotechnology leadership.“Importing socialized medicine will not make Americans healthier or our economy stronger. It will only serve to empower China and our other adversaries and undermine our economic and national security. Applying other countries’ antiquated approach to how they value – and pay – for medicines will stall investment across America’s biotech companies, risk access to vital treatments and cures for millions of American patients, and lead to fewer American jobs. “Patients and families are not a bargaining chip in a trade war, but that’s exactly how they are being treated – first through proposed tariffs on our nation’s medicines, now with foreign reference pricing in the name of fairness. "Researchers that spend years developing cures and breakthrough treatments are being penalized and the US is falling behind in the 21st century biotech race. Meanwhile, US medication prices prop up middlemen that prevent cost savings from being passed on to patients. The solution is investments that ensure the U.S. continues to lead the world in medical innovation, and policies that simplify the system."